First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.
BACKGROUND:Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-En...
Main Authors: | Kathryn E Stephenson, Michael C Keefer, Catherine A Bunce, Doreen Frances, Peter Abbink, Lori F Maxfield, George H Neubauer, Joseph Nkolola, Lauren Peter, Christopher Lane, Harriet Park, Carl Verlinde, Angela Lombardo, Christopher Yallop, Menzo Havenga, Patricia Fast, John Treanor, Dan H Barouch |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6235250?pdf=render |
Similar Items
-
Development of replication-competent adenovirus based vaccine vectors
by: Abbink P, et al.
Published: (2012-09-01) -
Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys
by: Brandon F. Keele, et al.
Published: (2017-06-01) -
Novel Adenovirus Vector-Based Vaccines for HIV
by: Letvin N, et al.
Published: (2005-12-01) -
Development of a novel simian adenovirus 24 based vaccine vector
by: Abbink P, et al.
Published: (2012-09-01) -
Adenovirus serotype 26 utilizes CD46 as primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
by: Li H, et al.
Published: (2012-09-01)